Mixed-Backbone Oligonucleotides for Therapeutics: The Way of the Future
- 1CSIR-Indian Institute of Chemical Technology , , Tarnaka , , ,
Abstract
Conventional oligonucleotides, such as DNA and RNA, are extensively modified for therapeutic applications. The mixed-backbone oligonucleotides (MBOs) that are generated by combining different classes have superior properties such as enhanced mRNA binding affinity, improved distribution, and reduced toxicity. Oligonucleotides act on mRNA in different ways, such as RNase H-mediated decay, RNA interference, and splice switching, and require specific modification patterns in each case. Hence, understanding the scope of different modifications and their synthetic compatibility is fundamental to the blueprint of future MBOs. In this Perspective, the important design considerations of mixed-backbone oligonucleotides have been presented for the most common types of mRNA-targeting oligonucleotides. The synthetic principles employed for the generation of chimeric MBOs using different phosphorus chemistries and execution modes (manual/automated) have also been discussed. Finally, the evolution of MBOs in clinical studies has been presented with exemplification of FDA-approved ONs.
Related
- Therapeutic oligonucleotides as genetic medicines: The current state and future perspective
- Pharmaceutical Applications of Nucleic Acid Aptamers: Recent Advances and Future Perspectives in Therapeutics, Biosensing, Bioanalysis, and Process Analysis
- DNA oligonucleotides encoding suppressor tRNA induce readthrough of premature termination codon
- Solution structure of oligonucleotides covalently linked to a psoralen derivative
- Thiomorpholino antisense oligonucleotides inhibit telomerase and limit cancer cell proliferation
BibTeX
@article{gupta2026mixedbackbone,
title = {{Mixed-Backbone Oligonucleotides for Therapeutics: The Way of the Future}},
author = {Shalini Gupta},
journal = {JACS Au},
year = {2026},
month = oct,
doi = {10.1021/jacsau.6c01239},
url = {https://pubs.acs.org/jaaucr/article/doi/10.1021/jacsau.6c01239/5456476/Mixed-Backbone-Oligonucleotides-for-Therapeutics},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Mixed-Backbone Oligonucleotides for Therapeutics: The Way of the Future
AU - Shalini Gupta
PY - 2026
DA - 2026/10/22
JO - JACS Au
DO - 10.1021/jacsau.6c01239
UR - https://pubs.acs.org/jaaucr/article/doi/10.1021/jacsau.6c01239/5456476/Mixed-Backbone-Oligonucleotides-for-Therapeutics
AB - Conventional oligonucleotides, such as DNA and RNA, are extensively modified for therapeutic applications. The mixed-backbone oligonucleotides (MBOs) that are generated by combining different classes have superior properties such as enhanced mRNA binding affinity, improved distribution, and reduced toxicity. Oligonucleotides act on mRNA in different ways, such as RNase H-mediated decay, RNA interference, and splice switching, and require specific modification patterns in each case. Hence, understanding the scope of different modifications and their synthetic compatibility is fundamental to the blueprint of future MBOs. In this Perspective, the important design considerations of mixed-backbone oligonucleotides have been presented for the most common types of mRNA-targeting oligonucleotides. The synthetic principles employed for the generation of chimeric MBOs using different phosphorus chemistries and execution modes (manual/automated) have also been discussed. Finally, the evolution of MBOs in clinical studies has been presented with exemplification of FDA-approved ONs.
SN - 2691-3704
ER -